Evidence map›Paper›PMID 40341475›Full record

ArticleEpilepsia2025

Trajectories of long-term survival after status epilepticus.

Camilla Dyremose Cornwall, Simon Bang Kristensen, Line Bedos Ulvin, Kjell Heuser, Erik Taubøll, Adam Strzelczyk, Susanne Knake, Felix Rosenow, Christoph Patrick Beier

Abstract read
In one paragraph

Article in Epilepsia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Camilla Dyremose CornwallDepartment of Neurology, Odense University Hospital, Odense, Denmark.
Simon Bang KristensenDepartment of Public Health, Aarhus University, Aarhus, Denmark.
Line Bedos UlvinDepartment of Neurology, Oslo University Hospital, Oslo, Norway.
Kjell HeuserDepartment of Neurology, Oslo University Hospital, Oslo, Norway.
Erik TaubøllDepartment of Neurology, Oslo University Hospital, Oslo, Norway.ORCID https://orcid.org/0000-0001-7208-7932
Adam StrzelczykEpilepsy Center Frankfurt Rhine-Main, Department of Neurology, Goethe-University Frankfurt, Frankfurt am Main, Germany.ORCID https://orcid.org/0000-0001-6288-9915
Susanne KnakeEpilepsy Center Hessen and Department of Neurology, Philipps-University, Marburg, Germany.
Felix RosenowEpilepsy Center Frankfurt Rhine-Main, Department of Neurology, Goethe-University Frankfurt, Frankfurt am Main, Germany.
Christoph Patrick BeierDepartment of Neurology, Odense University Hospital, Odense, Denmark.ORCID https://orcid.org/0000-0001-8268-1492

Funding

Lundbeck Foundation R434-2023-342
6 · The paper itself

Abstract

objectivesTo investigate the trajectories of clinical characteristics and prognostic factors among long-term survivors of status epilepticus (SE), given the high mortality during acute hospitalization and in subsequent years.

methodsAdult patients (≥18 years of age) with first-time, non-anoxic SE were identified and included from University Hospitals in Oslo (Norway), Odense (Denmark), Frankfurt, and Marburg (Germany). Demographics, etiology, comorbidities, and seizure characteristics were assessed. Poisson regression was used to model mortality rates over the follow-up period.

resultsBetween 2001 and 2017, we included 1306 patients (median follow-up: 17.4 months). The estimated cumulative proportion surviving at 3, 12, 24, and 36 months were 94.0%, 73.0%, 51.1%, and 39.5%, respectively, with a similar increase in mortality after discharge across all cohorts. Daily mortality peaked during the first 150 days; mortality trajectories differed depending on etiology, SE duration, and age. The clinical characteristics of survivors changed during long-term follow-up; long-term survivors (>36 months) were younger, had shorter SE durations, and had different underlying etiologies. The relative impact of different prognostic factors on the daily mortality shifted during long-term follow-up. Although most established prognostic factors strongly influenced in-hospital mortality, the relative impact of SE duration, comorbidities, and remote symptomatic etiologies first peaked after 6 months. SIGNIFICANCE: The optimal time point to assess survival in the acute phase is at 6 months, whereas evaluating survival after 2.5 years provides reliable estimates of long-term mortality. Assessing SE survival at discharge underestimates the impact of remote symptomatic etiologies and duration of SE on long-term survival.

Indexed as

Status EpilepticusSurvivorsAdultAgedDenmarkFemaleFollow-Up StudiesGermanyHumansMaleMiddle AgedNorwayPrognosisYoung Adultlong‐term mortalityprognosticationstatus epilepticustrajectory

Identifiers

PMID40341475
PMCPMC12371655

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.